Aura Biosciences (NASDAQ:AURA) Posts Earnings Results, Misses Estimates By $0.09 EPS

Aura Biosciences (NASDAQ:AURA) posted its earnings results on Monday. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.09), Zacks reports.

Aura Biosciences Trading Up 1.1 %

AURA stock opened at $7.08 on Wednesday. The firm has a 50 day moving average of $7.64 and a 200-day moving average of $8.66. Aura Biosciences has a 12 month low of $6.33 and a 12 month high of $12.38. The firm has a market capitalization of $353.65 million, a P/E ratio of -4.09 and a beta of 0.30.

Insider Transactions at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the sale, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. This trade represents a 4.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 23,045 shares of company stock valued at $177,242. 5.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a research report on Monday. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Aura Biosciences presently has a consensus rating of “Buy” and a consensus target price of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.